The next wave of cellular immunotherapies in pancreatic cancer
Pancreatic cancer is an aggressive disease that is predicted to become the second leading cause of cancer-related death worldwide by 2030. The overall 5-year survival rate is around 10%. Pancreatic cancer typically presents late with locally advanced or metastatic disease, and there are limited effe...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-03-01
|
| Series: | Molecular Therapy: Oncolytics |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2372770522000146 |
| _version_ | 1819282897894375424 |
|---|---|
| author | Dannel Yeo Caroline Giardina Payal Saxena John E.J. Rasko |
| author_facet | Dannel Yeo Caroline Giardina Payal Saxena John E.J. Rasko |
| author_sort | Dannel Yeo |
| collection | DOAJ |
| description | Pancreatic cancer is an aggressive disease that is predicted to become the second leading cause of cancer-related death worldwide by 2030. The overall 5-year survival rate is around 10%. Pancreatic cancer typically presents late with locally advanced or metastatic disease, and there are limited effective treatments available. Cellular immunotherapy, such as chimeric antigen receptor (CAR) T cell therapy, has had significant success in treating hematological malignancies. However, CAR T cell therapy efficacy in pancreatic cancer has been limited. This review provides an overview of current and ongoing CAR T cell clinical studies of pancreatic cancer and the major challenges and strategies to improve CAR T cell efficacy. These strategies include arming CAR T cells; developing off-the-shelf allogeneic CAR T cells; using other immune CAR cells, like natural killer cells and tumor-infiltrating lymphocytes; and combination therapy. Careful incorporation of preclinical models will enhance management of affected individuals, assisting incorporation of cellular immunotherapies. A multifaceted, personalized approach involving cellular immunotherapy treatment is required to improve pancreatic cancer outcomes. |
| first_indexed | 2024-12-24T01:22:53Z |
| format | Article |
| id | doaj.art-ab9dd6cf66f54278bb82356c5354131c |
| institution | Directory Open Access Journal |
| issn | 2372-7705 |
| language | English |
| last_indexed | 2024-12-24T01:22:53Z |
| publishDate | 2022-03-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Molecular Therapy: Oncolytics |
| spelling | doaj.art-ab9dd6cf66f54278bb82356c5354131c2022-12-21T17:22:36ZengElsevierMolecular Therapy: Oncolytics2372-77052022-03-0124561576The next wave of cellular immunotherapies in pancreatic cancerDannel Yeo0Caroline Giardina1Payal Saxena2John E.J. Rasko3Li Ka Shing Cell & Gene Therapy Program, The University of Sydney, Camperdown, NSW 2050, Australia; Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW 2050, Australia; Cell and Molecular Therapies, Royal Prince Alfred Hospital, Sydney Local Health District, Camperdown, NSW 2050, AustraliaFaculty of Medicine and Health, The University of Sydney, Camperdown, NSW 2050, Australia; Gene and Stem Cell Therapy Program, Centenary Institute, The University of Sydney, Camperdown, NSW 2050, AustraliaFaculty of Medicine and Health, The University of Sydney, Camperdown, NSW 2050, Australia; Division of Gastroenterology, Department of Medicine, Royal Prince Alfred Hospital, Sydney Local Health District, Camperdown, NSW 2050, AustraliaLi Ka Shing Cell & Gene Therapy Program, The University of Sydney, Camperdown, NSW 2050, Australia; Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW 2050, Australia; Cell and Molecular Therapies, Royal Prince Alfred Hospital, Sydney Local Health District, Camperdown, NSW 2050, Australia; Gene and Stem Cell Therapy Program, Centenary Institute, The University of Sydney, Camperdown, NSW 2050, Australia; Corresponding author John E.J. Rasko, Gene and Stem Cell Therapy Program, Centenary Institute, The University of Sydney, Camperdown, NSW 2050, Australia.Pancreatic cancer is an aggressive disease that is predicted to become the second leading cause of cancer-related death worldwide by 2030. The overall 5-year survival rate is around 10%. Pancreatic cancer typically presents late with locally advanced or metastatic disease, and there are limited effective treatments available. Cellular immunotherapy, such as chimeric antigen receptor (CAR) T cell therapy, has had significant success in treating hematological malignancies. However, CAR T cell therapy efficacy in pancreatic cancer has been limited. This review provides an overview of current and ongoing CAR T cell clinical studies of pancreatic cancer and the major challenges and strategies to improve CAR T cell efficacy. These strategies include arming CAR T cells; developing off-the-shelf allogeneic CAR T cells; using other immune CAR cells, like natural killer cells and tumor-infiltrating lymphocytes; and combination therapy. Careful incorporation of preclinical models will enhance management of affected individuals, assisting incorporation of cellular immunotherapies. A multifaceted, personalized approach involving cellular immunotherapy treatment is required to improve pancreatic cancer outcomes.http://www.sciencedirect.com/science/article/pii/S2372770522000146pancreatic cancercellular immunotherapyadoptive T cell therapyCAR T cell therapytumor microenvironmentcheckpoint blockade |
| spellingShingle | Dannel Yeo Caroline Giardina Payal Saxena John E.J. Rasko The next wave of cellular immunotherapies in pancreatic cancer Molecular Therapy: Oncolytics pancreatic cancer cellular immunotherapy adoptive T cell therapy CAR T cell therapy tumor microenvironment checkpoint blockade |
| title | The next wave of cellular immunotherapies in pancreatic cancer |
| title_full | The next wave of cellular immunotherapies in pancreatic cancer |
| title_fullStr | The next wave of cellular immunotherapies in pancreatic cancer |
| title_full_unstemmed | The next wave of cellular immunotherapies in pancreatic cancer |
| title_short | The next wave of cellular immunotherapies in pancreatic cancer |
| title_sort | next wave of cellular immunotherapies in pancreatic cancer |
| topic | pancreatic cancer cellular immunotherapy adoptive T cell therapy CAR T cell therapy tumor microenvironment checkpoint blockade |
| url | http://www.sciencedirect.com/science/article/pii/S2372770522000146 |
| work_keys_str_mv | AT dannelyeo thenextwaveofcellularimmunotherapiesinpancreaticcancer AT carolinegiardina thenextwaveofcellularimmunotherapiesinpancreaticcancer AT payalsaxena thenextwaveofcellularimmunotherapiesinpancreaticcancer AT johnejrasko thenextwaveofcellularimmunotherapiesinpancreaticcancer AT dannelyeo nextwaveofcellularimmunotherapiesinpancreaticcancer AT carolinegiardina nextwaveofcellularimmunotherapiesinpancreaticcancer AT payalsaxena nextwaveofcellularimmunotherapiesinpancreaticcancer AT johnejrasko nextwaveofcellularimmunotherapiesinpancreaticcancer |